Collaborations

InnoMedica cooperates with scientific institutions and clinics in order to further develop and make use of this promising technology platform. Together with the John A. Burns School of Medicine, applications in the field of arteriosclerosis are being researched. In collaboration with the University of Berne InnoMedica is developing a liposome for bacterial control without the use of antibiotics. Further national and international research collaborations are in development for the investigation of additional potential areas of application.

InnoMedica has partnered with the Swiss Group for Clinical Cancer Research (SAKK) to conduct the first clinical trial of Talidox. The starting point for the collaboration and initiation of the clinical trial was the joint analysis of Talidox’ preclinical efficacy and toxicity data.

SWISS ASSOCIATION FOR CLINICAL CANCER RESEARCH SAKK

The SAKK is a committed non-profit organization for clinical cancer research, and aims to explore new cancer therapies, improving existing treatments and to improve the prognosis of cancer patients. This is done through cooperation within Switzerland and in cooperation with foreign centers and study groups. The regular members of SAKK, the main clinical oncology centers at the cantonal and regional hospitals and university hospitals are organized together into an association. Since 1965, SAKK has been an independent Institution for multicenter clinical trials of Phases I, II and III through the major Swiss hospitals. Due to their network and experience are a strong partner, who can assist InnoMedica in carrying out the clinical trials.

The goal of the collaboration between SAKK and InnoMedica is to bring Talidox to the clinic as quickly as possible, whereby SAKK will carry out the clinical studies in the Swiss hospitals. The preclinical data set was well received by the SAKK oncologists involved: Talidox is said to have great potential as a new treatment option for cancer patients. After the review, the Executive Board of SAKK unanimously made the final decision to carry out the clinical trial with Talidox. Thanks to the great support of the project from the board of the SAKK and the high commitment of the project leaders, the development of the study protocol as the core of the study planning progressed rapidly and has been completed in the meantime.

In view of the urgent need for new treatment options in oncology, several qualified hospital centers have confirmed their participation in the study and are waiting for the trial to start as soon as possible:

  • Canton Hospital St. Gallen
  • Ospedale Regionale di Bellinzona e Valle (EOC) in Bellinzona
  • Inselspital Bern
  • Cantonal Hospital Graubünden
  • University Hospital Basel

The SAKK states in their press release:


«Since autumn 2012, InnoMedica has been developing the cancer therapy Talidox (Targeted Liposomal Doxorubicin), which aims to improve the biological availability of the cytotoxic drug Doxorubicin in patients thanks to a novel transport system. The active ingredient is wrapped in a lipid coat and the surface of the liposome is modified in such a way that increased accumulation in the tumor can be achieved.»

«This composition of the drug is classified by Swissmedic as a <known substance with innovation>, which permits a shorter registration. From the point of view of oncologists, this is a decisive advantage. The efficacy and tolerability of doxorubicin are well-known, and for liposomal formulations many years of experience are available in clinical practice. Thus, the efficacy is generally considered to be a given and the manufacturer must only show to what extent the changes of the drug influence the performance of the therapy.»

In autumn 2017, InnoMedica took up dialogue with leading neurologists from various clinics in Switzerland and nearby countries to evaluate potential collaborations for the implementation of clinical phase I and II trials with Talineuren. The response from physicians to InnoMedica’s long-term neuroprotective approach is extremely positive because it is not limited to alleviating symptoms like current therapies but is intended to prevent the progression of the disease.